A Phase 4 interventional study of Sofosbuvir and RBV in Hepatitis C Virus Infection, sponsored by Gilead Sciences. Completed at 17 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-03.
Sponsored by Gilead Sciences · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 94 studies testing sofosbuvir in Hepatitis C — 1 open to participants now, 3 under way, none of them phase 3. Sofosbuvir · Hepatitis C.
Among the 94 studies testing sofosbuvir in Hepatitis C, this one is the 50th largest by enrollment, is one of 11 that started in 2014, is one of 22 in phase 4, and was the 24th registered.
1,744 studies on the registry are indexed under Hepatitis C; 98 are open to participants now.
Browse Hepatitis C studies →1 of the 94 studies testing sofosbuvir in Hepatitis C is open now. Recruiting first, the newest first:
Eastern Idaho Public Health
Ages 18+
Sofosbuvir: first FDA approval 2013 (SOVALDI), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 56 Hepatitis C studies recruiting now, 43 (77%) set no upper age limit and 6 (11%) stop at 75 or younger; 10 take children under 18; 26 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 34 · Phase 3 31 · Phase 4 22
First in 2010; this study’s year is marked. 11 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 66 is close to the median of 73 across 1,224 interventional studies indexed under Hepatitis C.
Median enrollment 75 across the 94 interventional studies. Of the 78 that completed or were terminated, 50 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
48 of 94 have an industry lead sponsor. The 10 most frequent:
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
110 studies in Hepatitis C by Gilead Sciences: none open now, none under way, none of them phase 3. Of 109 finished, 79 (72%) have results posted.
Among the 110 studies in Hepatitis C by Gilead Sciences, this one is the 67th largest by enrollment of the 97 interventional ones that give a count, is one of 15 that started in 2014, is the only one in phase 4, and was the 52nd registered.
Gilead Sciences’s Hepatitis C studies by the year they started, since 2006.
None of the studies under way reaches primary completion within a year.
Among the 94 studies testing sofosbuvir in Hepatitis C, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Gilead Sciences’s 110 in Hepatitis C:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will examine the safety, tolerability, and antiviral efficacy of sofosbuvir (SOF)+ribavirin (RBV) in treatment-naive and treatment-experienced United States Veterans with compensated cirrhosis and genotype 2 HCV infection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Chronic genotype 2 (GT2) infection Classified as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive sofosbuvir+RBV for 12 weeks.
Drug: Sofosbuvir · Drug: RBV
Sofosbuvir 400 mg tablet administered orally once daily
Also known as: Sovaldi®, GS-7977, PSI-7977
Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.
Time frame: Posttreatment Week 12
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame: Up to 12 weeks
Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4)
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks following the last dose of study drug.
Time frame: Posttreatment Week 4
Percentage of Participants Experiencing Viral Breakthrough
Viral breakthrough was defined as either: * HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while receiving treatment * HCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values
Time frame: Up to Posttreatment Weak 12
Percentage of Participants Experiencing Viral Relapse
Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA \< LLOQ at end of treatment.
Time frame: Up to Posttreatment Week 12
Number of Participants With Nonstructural Protein 5B (NS5B) Nucleoside Inhibitor (NI) Resistance-Associated Variants (RAVs) and RBV RAVs at Pretreatment and Posttreatment
Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.
Time frame: Pretreatment and Posttreatment Week 12
Participants were enrolled at a total of 15 study sites in the United States The first participant was screened on 04 June 2014. The last study visit occurred on 22 June 2015.
| Milestone | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) |
|---|---|---|
| Started | 47 | 19 |
| Completed | 43 | 19 |
| Not completed | 4 | 0 |
| Withdrew: Lost to follow-up | 3 | 0 |
| Withdrew: Withdrew consent | 1 | 0 |
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 25 IU/mL) at 12 weeks after stopping study treatment.
| Percentage of participants | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy | 76.6 (62.0 to 87.7) | 84.2 (60.4 to 96.6) |
| Percentage of participants | SOF+RBV 12 Weeks (All) |
|---|---|
| Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | 4.5 |
SVR4 was defined as HCV RNA \< LLOQ at 4 weeks following the last dose of study drug.
| percentage of participants | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) |
|---|---|---|
| Percentage of Participants With Sustained Virologic Response at 4 Weeks After Discontinuation of Therapy (SVR4) | 78.7 (64.3 to 89.3) | 89.5 (66.9 to 98.7) |
Viral breakthrough was defined as either: * HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while receiving treatment * HCV RNA ≥ LLOQ at the last available on-treatment measurement with no subsequent follow-up values
| Percentage of participants | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) |
|---|---|---|
| Percentage of Participants Experiencing Viral Breakthrough | 0 | 0 |
Viral relapse was defined as HCV RNA ≥ LLOQ during the posttreatment period after having achieved HCV RNA \< LLOQ at end of treatment.
| Percentage of participants | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) |
|---|---|---|
| Percentage of Participants Experiencing Viral Relapse | 17.4 | 15.8 |
Deep sequencing of the HCV NS5B gene was attempted for all participants who had virologic failure at pretreatment and posttreatment time points if the level of HCV RNA in the plasma sample was ≥ 1000 IU/L.
| participants | SOF+RBV 12 Weeks (All) |
|---|---|
| NS5B NI RAV Pretreatment | 2 |
| NS5B NI RAV Posttreatment | 5 |
| NS5B RBV RAV Pretreatment | 0 |
| NS5B RBV RAV Posttreatment | 0 |
Collected over Up to12 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| SOF+RBV 12 Weeks (All Participants) | — | 8/66 (12.1%) | 45/66 (68.2%) |
| Event | SOF+RBV 12 Weeks (All Participants) |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 1/66 |
| Cardiac failure congestiveCardiac disorders | 1/66 |
| NauseaGastrointestinal disorders | 1/66 |
| Oesophageal varices haemorrhageGastrointestinal disorders | 1/66 |
| Chest painGeneral disorders | 1/66 |
| BacteraemiaInfections and infestations | 1/66 |
| Endocarditis staphylococcalInfections and infestations | 1/66 |
| SepsisInfections and infestations | 1/66 |
| RhabdomyolysisMusculoskeletal and connective tissue disorders | 1/66 |
| Drug withdrawal convulsionsNervous system disorders | 1/66 |
| Event | SOF+RBV 12 Weeks (All Participants) |
|---|---|
| FatigueGeneral disorders | 22/66 |
| AnaemiaBlood and lymphatic system disorders | 16/66 |
| NauseaGastrointestinal disorders | 12/66 |
| HeadacheNervous system disorders | 11/66 |
| DizzinessNervous system disorders | 6/66 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 5/66 |
| RashSkin and subcutaneous tissue disorders | 5/66 |
| DiarrhoeaGastrointestinal disorders | 4/66 |
| DyspepsiaGastrointestinal disorders | 4/66 |
| VomitingGastrointestinal disorders | 4/66 |
Safety analysis set: participants who received at least 1 dose of study drug
| Age, Continuous(Years) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| Mean | 64 ± 6.0 | 62 ± 5.4 | 63 ± 5.8 |
| Sex: Female, Male(Participants) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 47 | 19 | 66 |
| Race/Ethnicity, Customized(participants) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| Black or African American | 8 | 2 | 10 |
| White | 37 | 17 | 54 |
| Hawaiian or Pacific Islander | 1 | 0 | 1 |
| Other | 1 | 0 | 1 |
| Region of Enrollment(participants) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| United States | 47 | 19 | 66 |
| IL28b Status(participants) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| CC | 25 | 8 | 33 |
| CT | 19 | 10 | 29 |
| TT | 3 | 1 | 4 |
| HCV RNA(log10 IU/mL) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| Mean | 5.9 ± 0.89 | 6.6 ± 0.48 | 6.1 ± 0.87 |
| HCV RNA Category(participants) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| < 800,000 IU/mL | 21 | 2 | 23 |
| ≥ 800,000 IU/mL | 26 | 17 | 43 |
| HCV Genotype(participants) | SOF+RBV 12 Weeks (TN) | SOF+RBV 12 Weeks (TE) | Total |
|---|---|---|---|
| Genotype 2 | 2 | 2 | 4 |
| Genotype 2b | 37 | 17 | 54 |
| Genotype 2a/2c | 8 | 0 | 8 |
1 further baseline measures are reported on the registry.
The record gives a start of Jun 2014, a primary completion of Jun 2015 and a completion of Jun 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2016, 1 year 2 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Sofosbuvir · Ribavirin